197 related articles for article (PubMed ID: 22049854)
1. Laws fail to slow gray market. Concerns raised over secondary drug distributors.
Lee J
Mod Healthc; 2011 Oct; 41(40):14. PubMed ID: 22049854
[No Abstract] [Full Text] [Related]
2. Shades of gray. Secondary drug distributors raise questions.
Lee J
Mod Healthc; 2011 Oct; 41(41):10, 12. PubMed ID: 22111494
[No Abstract] [Full Text] [Related]
3. Plenty of green in gray market. There's more at issue than just inflated prices for drugs in short supply.
May D
Mod Healthc; 2011 Oct; 41(42):25. PubMed ID: 22049782
[No Abstract] [Full Text] [Related]
4. Pharmaceuticals and medical devices: FDA oversight.
Chaps NA
Issue Brief Health Policy Track Serv; 2009 Jan; ():1-28. PubMed ID: 19297718
[No Abstract] [Full Text] [Related]
5. Omnicare forgot to mention ... Part D's effect not factored in its argument for hostile PharMerica takeover.
Lee J
Mod Healthc; 2012 Feb; 42(6):14. PubMed ID: 22356083
[No Abstract] [Full Text] [Related]
6. Running short.
Mettner J
Minn Med; 2011 Oct; 94(10):8-10. PubMed ID: 23256277
[No Abstract] [Full Text] [Related]
7. Drug-diversion turf war: will Cardinal ruling reinvent roles, DEA strategy?
Lee J
Mod Healthc; 2012 Mar; 42(10):8-9. PubMed ID: 22458066
[No Abstract] [Full Text] [Related]
8. Pharmaceuticals and medical devices: business practices.
; Steiner DJ
Issue Brief Health Policy Track Serv; 2014 Dec; ():1-38. PubMed ID: 25771555
[No Abstract] [Full Text] [Related]
9. Analysis of State-Level Drug Pricing Transparency Laws in the United States.
Ryan MS; Sood N
JAMA Netw Open; 2019 Sep; 2(9):e1912104. PubMed ID: 31553467
[TBL] [Abstract][Full Text] [Related]
10. Pharmaceuticals and the health of the public: use, safety, cost, access, ethics, and quality.
Zito JM
Med Care; 2012 Nov; 50(11):907-9. PubMed ID: 23047777
[No Abstract] [Full Text] [Related]
11. Counterfeit medications: impurities in the american drug supply.
Stoneman A; Simon S; Trahan J
J Midwifery Womens Health; 2011; 56(6):636-8. PubMed ID: 22060224
[No Abstract] [Full Text] [Related]
12. White House addresses drug shortages.
Traynor K
Am J Health Syst Pharm; 2011 Dec; 68(23):2204, 2206. PubMed ID: 22095801
[No Abstract] [Full Text] [Related]
13. Drug shortages--Congress listens, FDA acts.
Thompson CA
Am J Health Syst Pharm; 2012 Jan; 69(2):90-1. PubMed ID: 22215347
[No Abstract] [Full Text] [Related]
14. Qui tam: False Claims Act.
Salcido R
Adv Skin Wound Care; 2010 Nov; 23(11):487. PubMed ID: 20975328
[No Abstract] [Full Text] [Related]
15. McKesson settling up. $190 million payment latest in drug-price flap.
Carlson J
Mod Healthc; 2012 Apr; 42(18):14. PubMed ID: 22667036
[No Abstract] [Full Text] [Related]
16. Access to safety data--stockholders versus prescribers.
Pfeffer MA; Bowler MB
N Engl J Med; 2011 Jul; 365(1):1-3. PubMed ID: 21714642
[No Abstract] [Full Text] [Related]
17. Using market-exclusivity incentives to promote pharmaceutical innovation.
Kesselheim AS
N Engl J Med; 2010 Nov; 363(19):1855-62. PubMed ID: 21047231
[No Abstract] [Full Text] [Related]
18. Enforcement actions involving Medicaid fraud and abuse, 1996-2009.
Qureshi ZP; Liu Y; Sartor O; Chu YH; Bennett CL
Arch Intern Med; 2011 Apr; 171(8):785-7. PubMed ID: 21518950
[No Abstract] [Full Text] [Related]
19. 'Must-pass' FDA fee renewal jammed with sunscreen and more.
Scheinbaum C
Nat Med; 2012 Jul; 18(7):990. PubMed ID: 22772529
[No Abstract] [Full Text] [Related]
20. On the same page: House, Senate FDA bills move toward passage.
Daly R
Mod Healthc; 2012 Jun; 42(23):8-9. PubMed ID: 22745963
[No Abstract] [Full Text] [Related]
[Next] [New Search]
